**Abstract**

**Background:** Obesity has emerged as a leading health threat and major risk factor for type 2 diabetes, cardiovascular disease, and hypertension. The neurobiological basis of overeating remains insufficiently known, hampering sufficient intervention strategies. Here we investigate oleoylethanolamide, an agonist of PPAR-α. It has been implicated in weight regulation in animals but its respective role in humans is still unclear.

**Methods:** Associations between plasma oleoylethanolamide, BMI and associated neurobiological impact (fMRi response to food stimuli) in 21 obese patients (BMI≥30) and 24 controls were investigated. We hypothesized that oleoylethanolamide interacts with BMI and fMRI response to food stimuli and may be affected in obese patients.

**Results:** Associations between oleoylethanolamide and BMI differed significantly depending on whether subjects were obese or not (P=0.02). For obese individuals, oleoylethanolamide showed a trend towards a positive correlation with BMI (P=0.06, rho=0.42) while this relationship was inverse for controls (P=0.07, rho=-0.34). We observed significant interactions between oleoylethanolamide and obesity on food-related brain activation in cortical areas associated with reward processing and interoceptive signaling (P=0.009). fMRI-investigation of food-craving suggests that identified brain areas may be involved in suppressing 'liking' of food, in non-obese subjects.

**Conclusions:** Oleoylethanolamide modulates motivation of intra-gastric feeding, possibly through normalization of PPAR-α-dependent vagal feedback to the brain in rodents. This supports its homeostatic function for regulating dietary fat intake via vagal-nigro-striatal pathways. Our study suggests that oleoylethanolamide mediates reward-associated neural processes and this signaling plays an important role for hedonic regulation of food-craving and obesity in humans. It may be a valuable target for developing novel anti- obesity drugs.
